發(fā)布時(shí)間：2018-08-12 11:14

【摘要】： 目的構(gòu)建單純皰疹病毒2型(HSV-2)糖蛋白gD、gB、gC和早期表達(dá)蛋白ICP 27的多表位復(fù)合DNA疫苗和免疫佐劑IL2質(zhì)粒，以及在復(fù)合疫苗質(zhì)粒基礎(chǔ)上修飾的信號肽質(zhì)粒與泛素化質(zhì)粒，并探討其誘導(dǎo)小鼠機(jī)體免疫應(yīng)答的能力。 方法國內(nèi)HSV-2野生株經(jīng)PCR鑒定后利用PCR技術(shù)從其基因組中擴(kuò)增出HSV-2 ICP27 377-459、gD146-179、gD223-306、gB529-606、gC247-282、gD1-77六個(gè)基因片段，PCR鑒定后按先后順序，采用多基因片段一步酶切連接法獲得HV融合基因片段，經(jīng)pGEMT載體克隆后定向插入真核表達(dá)質(zhì)粒pcDNA3.1載體中，構(gòu)建出重組真核表達(dá)質(zhì)粒HV-pcDNA3.1，并對其進(jìn)行酶切分析及測序鑒定。 PCR擴(kuò)增gD146-179信號肽片段，進(jìn)一步酶切連接構(gòu)建重組質(zhì)粒gDs-HV-his-pcDNA3.1，并對其進(jìn)行酶切分析及測序鑒定。 PCR擴(kuò)增人基因組DNA和HSV-2基因組中泛素全長基因和HSV-2 ICP27 377-459，酶切連接獲得融合基因片段，插入真核表達(dá)質(zhì)粒pcDNA3.1載體中，構(gòu)建出重組質(zhì)粒Ub-ICP-pcDNA3.1，并對其進(jìn)行酶切分析及測序鑒定。 PCR擴(kuò)增人IL-2信號肽基因和人IL-2尾段基因，取上述兩段PCR擴(kuò)增產(chǎn)物作為融合PCR的模板，擴(kuò)增IL-2 cDNA全長基因，連入pcDNA3.1質(zhì)粒中，構(gòu)建出重組質(zhì)粒IL-2-pcDNA3.1，并對其進(jìn)行酶切分析及測序鑒定。 C57／BL6雌性6周齡小鼠40只，隨機(jī)分為8組，每組均5只，根據(jù)免疫的質(zhì)粒類型和免疫方式的不同，各組依次為pcDNA3.1(空質(zhì)粒對照)、HV-pcDNA3.1、HV-pcDNA3.1+IL2-pcDNA3.1、gDs-HV-his-pcDNA3.1、gDs-HV-his-pcDNA3.1+IL2-pcDNA3.1、Ub-ICP-pcDNA3.1和HV-pcDNA3.1、HV-pcDNA3.1+IL2-pcDNA3.1。 免疫前先用特異性抗原刺激，前6組小鼠每只用5ug的相應(yīng)質(zhì)粒(與IL2共表達(dá)的組用5+5ug的量)和1ug的脂質(zhì)體充分混合，，20min后轉(zhuǎn)染到同批次C57／BL6雌性鼠脾淋巴細(xì)胞中，37℃、5％CO_2培養(yǎng)4h后注射入小鼠皮下；后2組小鼠也用5ug的相應(yīng)質(zhì)粒(與IL2共表達(dá)的組用5+5ug的量)直接注射到雙側(cè)脛骨前肌中。14天后正式免疫，前6組小鼠每只用100ug的相應(yīng)質(zhì)粒(與IL2共表達(dá)的組用100+100ug的量)和10ug的脂質(zhì)體充分混合，20min后注入小鼠雙側(cè)脛骨前肌中；后2組小鼠也用100ug的相應(yīng)質(zhì)粒(與IL2共表達(dá)的組用100+100ug的量)直接注入小鼠雙側(cè)脛骨前肌中。14天后再加強(qiáng)免疫一次，方法和劑量與正式免疫完全一致。 加強(qiáng)免疫后3周小鼠斷尾取血，分離血清。斷頸處死小鼠取脾，分離淋巴細(xì)胞。ELISA檢測小鼠血清HSV-2特異性IgG、IL-2和IFN-γ，MTT法檢測小鼠脾T淋巴細(xì)胞特異性增殖，乳酸脫氫酶法檢測殺傷性T淋巴細(xì)胞(CTL)功能和流式細(xì)胞儀檢測CD4+／CD8+T細(xì)胞亞群分類。 結(jié)果構(gòu)建的HV-pcDNA3.1質(zhì)粒、IL2-pcDNA3.1質(zhì)粒、Ub-ICP-pcDNA3.1質(zhì)粒、gDs-HV-his-pcDNA3.1質(zhì)粒經(jīng)酶切鑒定并進(jìn)行DNA測序，測序結(jié)果正確，表明已成功構(gòu)建出HSV-2多表位復(fù)合DNA疫苗。 免疫小鼠后實(shí)驗(yàn)結(jié)果顯示：gDs-HV-his-pcDNA3.1與IL2-pcDNA3.1聯(lián)合免疫后體液免疫最強(qiáng)，特異性IgG效價(jià)達(dá)到400倍左右；T細(xì)胞表面信號分子CD4的陽性率與空載體pcDNA3.1組相比有顯著差異(P＜0.05)。而HV-pcDNA3.1與IL2-pcDNA3.1聯(lián)合免疫后細(xì)胞免疫水平最強(qiáng)，特異性T淋巴細(xì)胞的刺激指數(shù)SI達(dá)到2.75左右，而空質(zhì)粒對照組為0.7左右；淋巴細(xì)胞殺傷實(shí)驗(yàn)CTL反應(yīng)的殺傷率(效靶比為50：1時(shí))接近50％，而空質(zhì)粒對照組為8％左右；T細(xì)胞表面信號分子CD8的陽性率與空載體pcDNA3.1組相比也有顯著差異(P＜0.05)，但CD4~+／CD8~+的值無顯著差異(P＞0.05)；血清中細(xì)胞因子IL2和IFN-γ含量檢測結(jié)果顯示：IL2水平(ng／L)為1421.16±220.98，而空質(zhì)粒對照組為685.21±104.20；IFN-γ水平(ng／L)為1956.19±219.60，而空質(zhì)粒對照組為547.71±189.33。 另一組有關(guān)不同免疫方式比較的實(shí)驗(yàn)總體上看則說明了脂質(zhì)體包裹的DNA疫苗比單純的裸DNA注射法能顯著提高免疫活性，若用脂質(zhì)體包裹起來同時(shí)轉(zhuǎn)染IL2質(zhì)粒和復(fù)合疫苗質(zhì)粒則更強(qiáng)。 結(jié)論 1．成功構(gòu)建了HSV-2多表位復(fù)合DNA疫苗，包括質(zhì)粒HV-pcDNA3.1、信號肽質(zhì)粒gDs-HV-his-pcDNA3.1、泛素化質(zhì)粒Ub-ICP-pcDNA3.1和佐劑質(zhì)粒IL2-pcDNA3.1。 2．小鼠動物實(shí)驗(yàn)表明，我們構(gòu)建的疫苗質(zhì)粒HV-pcDNA3.1和信號肽質(zhì)粒gDs-HV-his-pcDNA3.1能有效誘導(dǎo)小鼠體液免疫和細(xì)胞免疫應(yīng)答，與佐劑質(zhì)粒IL2-pcDNA3.1共同免疫效果更強(qiáng)。信號肽質(zhì)粒gDs-HV-his-pcDNA3.1與佐劑質(zhì)粒IL2-pcDNA3.1共注射誘導(dǎo)的體液免疫反應(yīng)最強(qiáng)，而質(zhì)粒HV-pcDNA3.1與佐劑質(zhì)粒IL2-pcDNA3.1共注射誘導(dǎo)的細(xì)胞免疫反應(yīng)最強(qiáng)。 3．質(zhì)粒經(jīng)脂質(zhì)體包裹并在免疫前通過淋巴細(xì)胞體外轉(zhuǎn)染小鼠皮下預(yù)注射方法比單純裸質(zhì)粒注射方法能明顯提高體液免疫和細(xì)胞免疫反應(yīng)。 4．泛素化質(zhì)粒Ub-ICP-pcDNA3.1不能誘導(dǎo)有效的體液免疫和細(xì)胞免疫應(yīng)答。
[Abstract]:Objective To construct a multi-epitope compound DNA vaccine and immune adjuvant IL-2 plasmid of herpes simplex virus-2 (HSV-2) glycoprotein gD, gB, gC and early expression protein ICP-27, as well as a signal peptide plasmid and a ubiquitination plasmid modified on the basis of the composite vaccine plasmid, and to investigate the ability of the plasmid to induce immune response in mice.
Methods Six gene fragments of HSV-2 ICP27 377-459, gD146-179, gD223-306, gB529-606, gC247-282 and gD1-77 were amplified from the genome of HSV-2 wild strain in China by PCR. The fragments of HV fusion gene were cloned by pGEMT vector and inserted directionally. The recombinant eukaryotic expression plasmid HV-pcDNA3.1 was constructed and identified by enzyme digestion and sequencing.
The gD146-179 signal peptide fragment was amplified by PCR, and the recombinant plasmid gDs-HV-his-pcDNA3.1 was constructed by enzyme digestion and ligation.
Full-length ubiquitin gene and HSV-2 ICP27 377-459 in human genome DNA and HSV-2 genome were amplified by PCR. Fusion gene fragments were obtained by enzyme digestion and ligation. The recombinant plasmid Ub-ICP-pcDNA3.1 was constructed by inserting into eukaryotic expression plasmid pcDNA3.1 vector. The recombinant plasmid Ub-ICP-pcDNA3.1 was analyzed by enzyme digestion and sequenced.
The full-length gene of IL-2 cDNA was amplified by PCR. The recombinant plasmid IL-2-pcDNA3.1 was constructed and identified by restriction enzyme digestion and sequencing.
C57/BL6 female mice aged 6 weeks were randomly divided into 8 groups. Each group consistof 5 mice randomly divided into 8 groups. According to the different immunplasmid types and immunimmunmodes, each group was pcDNA3.1 (blankplasmid control), HV-pcDNA3.1, HV-pcDNA3.1, HV-pcDNA3.1+IL2-pcDNA3.1, HV-pcDNA3.1+IL2-pcDNA3.1, HV-pcDNA3.1+IL2-pcDNA3.1, gDs-HV-HV-his-pcDNA3.1, gDs-HV-HV-pcDNA3.1+his-pcDNA3.1, gDDs-HDs-HV-HV-pcDNA3.1+IL2-ppcDNA 3.1.
The mice in the first six groups were stimulated with specific antigens before immunization. Each mouse in the first six groups was adequately mixed with the corresponding plasmids of 5+5 UG (the amount of 5+5 UG in the group co-expressed with IL2) and the liposome of 1 ug. The spleen lymphocytes of the same batch of C57/BL6 female mice were transfected 20 minutes later. The spleen lymphocytes were cultured at 37 C for 4 hours with 5% CO_2 and injected subcutaneously into the mice in the second two groups with the corresponding plasmids of 5 UG (the L2 co-expression group was injected directly into bilateral anterior tibial muscles with the dose of 5+5ug. 14 days later, the mice in the first six groups were immunized with 100 UG of corresponding plasmids (100+100ug of the group co-expressed with IL2) and 10 UG of liposome. After 20 minutes, the mice in the latter two groups were injected into bilateral anterior tibial muscles with 100 UG of corresponding plasmids (with IL2). The expression group was injected directly into the bilateral anterior tibial muscles of mice with the dose of 100 + 100 ug. The method and dose of the immunotherapy were completely consistent with the formal immunization.
Three weeks after the immunization, the mice were killed by neck-cutting and the spleens were taken out for lymphocyte isolation. The specific IgG, IL-2 and IFN-gamma of HSV-2 in serum were detected by ELISA, the specific proliferation of splenic T lymphocyte was detected by MTT, the killer T lymphocyte (CTL) function was detected by lactate dehydrogenase assay and the CD4 + / CD8 + T cell was detected by flow cytometry. Classification of subgroups.
Results The constructed HV-pcDNA3.1 plasmid, IL2-pcDNA3.1 plasmid, Ub-ICP-pcDNA3.1 plasmid and gDs-HV-his-pcDNA3.1 plasmid were identified by enzyme digestion and DNA sequencing. The results showed that the HSV-2 multi-epitope compound DNA vaccine was successfully constructed.
The results showed that the combined immunization of gDs-HV-his-pcDNA3.1 and IL2-pcDNA3.1 had the strongest humoral immunity, and the specific IgG titer was about 400 times. The positive rate of CD4 on T cell surface was significantly different from that of pcDNA3.1 group (P < 0.05). The stimulus index SI of specific T lymphocyte reached about 2.75, while that of blank plasmid control group was about 0.7; the killing rate of CTL reaction in lymphocyte killing experiment (the effective target ratio was 50:1) was close to 50%, while that of blank plasmid control group was about 8%; the positive rate of CD 8 on T cell surface signal molecule was also obvious compared with blank vector pcDNA3.1 group. There was significant difference (P < 0.05), but there was no significant difference (P > 0.05) in CD4 + / CD8 +; the levels of IL 2 and IFN - gamma in serum were 1421.16 + 220.98, 685.21 + 104.20 in blank plasmid control group, 1956.19 + 219.60 in ng / L, 547.71 + 189.33 in empty plasmid control group.
Another group of experiments comparing different immune modes showed that liposome-encapsulated DNA vaccines could significantly improve the immune activity compared with bare DNA vaccines, and the liposome-encapsulated DNA vaccines could transfect IL2 plasmids and composite vaccine plasmids simultaneously.
conclusion
1. HSV-2 multi-epitope DNA vaccine was successfully constructed, including plasmid HV-pcDNA3.1, signal peptide plasmid gDs-HV-his-pcDNA3.1, ubiquitinated plasmid Ub-ICP-pcDNA3.1 and adjuvant plasmid IL2-pcDNA3.1.
2. Animal experiments in mice showed that the Vaccine Plasmid HV-pcDNA3.1 and the signal peptide plasmid gDs-HV-his-pcDNA3.1 could effectively induce humoral and cellular immune responses in mice, and the co-immunization effect was stronger with the adjuvant plasmid IL2-pcDNA3.1. The signal peptide plasmid gDs-HV-his-pcDNA3.1 and the adjuvant plasmid IL2-pcDNA3.1 co-injected to induce humoral immunity. The strongest immune response was induced by co-injection of plasmid HV-pcDNA3.1 and adjuvant plasmid IL2-pcDNA3.1.
3. Subcutaneous pre-injection of plasmid encapsulated in liposome and transfected with lymphocytes in vitro before immunization can significantly improve humoral and cellular immune responses compared with bare plasmid injection.
4. ubiquitin plasmid Ub-ICP-pcDNA3.1 can not induce effective humoral and cellular immune responses.
【學(xué)位授予單位】：復(fù)旦大學(xué)
【學(xué)位級別】：博士
【學(xué)位授予年份】：2006
【分類號】：R392;R752.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 吳春利;程小雯;呂星;房師松;王昕;;A型流感病毒M基因DNA疫苗載體構(gòu)建及免疫性研究[J];中國熱帶醫(yī)學(xué);2011年07期

2 齊文娟;方強(qiáng);;寄生蟲病DNA疫苗研究進(jìn)展[J];中國血吸蟲病防治雜志;2011年03期

3 李晨晨;于繼云;姜敏;涂亦嫻;馬曉林;張富春;;草原兔尾鼠卵透明帶3DNA疫苗pVAX1-sig-LTB-lZP3-C3d3的構(gòu)建表達(dá)及其免疫不育的研究[J];細(xì)胞與分子免疫學(xué)雜志;2011年09期

4 鄧璐;鄒墨;劉艷;羅恩杰;;DNA疫苗的轉(zhuǎn)運(yùn)途徑及其安全性研究進(jìn)展[J];醫(yī)學(xué)動物防制;2011年08期

5 張亮;閻瑾琦;王越;肖毅;高昆;董金凱;王博;于繼云;;可復(fù)制型抗腫瘤DNA疫苗PSCK-2PFcGB的構(gòu)建及體內(nèi)外表達(dá)[J];南方醫(yī)科大學(xué)學(xué)報(bào);2011年06期

6 胡方靖;武軍駐;;pIHsp65GM的構(gòu)建及其對結(jié)核桿菌感染小鼠的保護(hù)[J];免疫學(xué)雜志;2011年08期

7 張陽;王英麗;;MUC1基因疫苗對乳腺腫瘤抑制的實(shí)驗(yàn)研究[J];中國婦幼保健;2011年21期

8 ;[J];;年期

9 ;[J];;年期

10 ;[J];;年期

相關(guān)會議論文 前10條

1 居巍;劉君炎;;結(jié)核桿菌HSP65佐劑DNA疫苗的實(shí)驗(yàn)研究[A];第6次全國微生物學(xué)與免疫學(xué)大會論文摘要匯編[C];2004年

2 姜秀云;何昭陽;;活體電穿孔法導(dǎo)入DNA:牛結(jié)核病免疫接種新技術(shù)[A];人畜共患傳染病防治研究新成果匯編[C];2004年

3 靳彥文;鐘輝;馬清鈞;;惡性瘧原蟲DNA疫苗的安全性研究[A];中國生物工程學(xué)會第三次全國會員代表大會暨學(xué)術(shù)討論會論文摘要集[C];2001年

4 田潔;劉君炎;;ConA與結(jié)核桿菌HSP65DNA疫苗聯(lián)合應(yīng)用的研究[A];湖北省暨武漢市免疫學(xué)會第八屆學(xué)術(shù)會議論文集[C];2003年

5 熊金虎;趙民;邱小萍;伍欣星;;人乳頭瘤病毒嵌合型DNA疫苗的構(gòu)建及其免疫效應(yīng)研究[A];湖北省暨武漢市生物化學(xué)與分子生物學(xué)學(xué)會第七屆第十四次學(xué)術(shù)年會論文摘要集[C];2003年

6 江云波;方六榮;肖少波;牛傳雙;張輝;陳煥春;;修飾的ORF5基因增強(qiáng)豬繁殖與呼吸綜合征DNA疫苗的免疫反應(yīng)[A];中國畜牧獸醫(yī)學(xué)會畜牧獸醫(yī)生物技術(shù)學(xué)分會暨中國免疫學(xué)會獸醫(yī)免疫分會第六次研討會論文集[C];2005年

7 吳長有;;DNA疫苗與免疫記憶[A];2005全國第二屆核酸疫苗研討會論文集[C];2005年

8 崔保安;魏戰(zhàn)勇;楊明凡;張素梅;;DNA疫苗免疫佐劑的研究進(jìn)展[A];中國畜牧獸醫(yī)學(xué)會家畜傳染病學(xué)分會成立20周年慶典暨第十次學(xué)術(shù)研討會論文集（上）[C];2003年

9 楊慧蘭;葛夢林;楊太成;劉榮卿;;單純皰疹病毒gD2 DNA疫苗免疫動物誘導(dǎo)的細(xì)胞免疫應(yīng)答[A];2003中國中西醫(yī)結(jié)合皮膚性病學(xué)術(shù)會議論文匯編[C];2003年

10 張冉;易新元;曾憲芳;;日本血吸蟲新基因克隆及DNA疫苗的構(gòu)建和保護(hù)性研究[A];中國動物學(xué)會全國第九次寄生蟲學(xué)學(xué)術(shù)討論會論文摘要集[C];2003年

相關(guān)重要報(bào)紙文章 前10條

1 蔣明 周漢橋;DNA疫苗研究取得突破[N];健康報(bào);2005年

2 林明貴 金關(guān)甫;DNA疫苗 戰(zhàn)勝結(jié)核的希望[N];健康報(bào);2003年

3 ;防治早老性癡呆DNA疫苗問世[N];新華每日電訊;2004年

4 ;DNA疫苗“餓”殺小鼠腫瘤[N];醫(yī)藥經(jīng)濟(jì)報(bào);2003年

5 陳勇;西尼羅病毒DNA疫苗開始臨床試驗(yàn)[N];健康報(bào);2005年

6 梅子;期待從今天開始[N];醫(yī)藥經(jīng)濟(jì)報(bào);2001年

7 劉恕;艾滋病疫苗離我們還有多遠(yuǎn)[N];科技日報(bào);2005年

8 本報(bào)記者 王玲 柯玲;中國艾滋病疫苗與時(shí)間賽跑[N];經(jīng)濟(jì)日報(bào);2005年

9 曲國斌;征服艾滋病不是夢[N];健康報(bào);2001年

10 何雁;何大一：傾心祖國艾滋病防治[N];人民日報(bào)海外版;2005年

相關(guān)博士學(xué)位論文 前10條

1 張洪英;口蹄疫多表位DNA疫苗的免疫原性和安全性研究[D];第二軍醫(yī)大學(xué);2003年

2 張靜;輪狀病毒分子流行病學(xué)調(diào)查及脂質(zhì)體DNA疫苗研究[D];重慶醫(yī)科大學(xué);2002年

3 王濤;嗜肺軍團(tuán)菌mip基因DNA疫苗初步研究[D];四川大學(xué);2004年

4 宋立強(qiáng);異種同源鈣激活Cl～-通道DNA疫苗對小鼠哮喘模型的防治作用[D];第四軍醫(yī)大學(xué);2004年

5 時(shí)陽;MAGE-1與IL-18共表達(dá)DNA疫苗的構(gòu)建及體內(nèi)外功能驗(yàn)證[D];吉林大學(xué);2004年

6 郭瀛軍;豬帶絳蟲囊蟲病DNA疫苗的中試及免疫效力研究[D];第二軍醫(yī)大學(xué);2004年

7 張夢寒;漢城病毒M片段和漢灘病毒部分S片段核酸疫苗pEGFP-M-S的構(gòu)建及基因免疫研究[D];蘇州大學(xué);2005年

8 焦解歌;豬Endoglin DNA疫苗誘導(dǎo)抗腫瘤血管生成機(jī)理研究[D];中南大學(xué);2005年

9 郭慧琛;O型口蹄疫病毒多基因DNA疫苗的研制[D];中國農(nóng)業(yè)科學(xué)院;2004年

10 張含;口服DNA疫苗防治實(shí)驗(yàn)性脈絡(luò)膜血管新生[D];中國醫(yī)科大學(xué);2005年

相關(guān)碩士學(xué)位論文 前10條

1 張恒;雞貧血病毒DNA疫苗的研究[D];山東師范大學(xué);2003年

2 曾政;布魯氏菌新型疫苗的構(gòu)建及其免疫原性研究[D];西北農(nóng)林科技大學(xué);2004年

3 楊帆;雞傳染性支氣管炎病毒分離株IBV_（WHNJ）M基因DNA疫苗研究[D];四川農(nóng)業(yè)大學(xué);2004年

4 楊璇;癌胚抗原DNA疫苗的構(gòu)建及佐劑對其免疫效應(yīng)的影響[D];鄭州大學(xué);2002年

5 黃力;口蹄疫多表位DNA疫苗的免疫原性[D];河北醫(yī)科大學(xué);2004年

6 張強(qiáng)哲;H5亞型禽流感病毒HA DNA疫苗的研究[D];西北農(nóng)林科技大學(xué);2003年

7 蔣英;白細(xì)胞介素12對結(jié)核病DNA疫苗效應(yīng)的增強(qiáng)作用[D];重慶醫(yī)科大學(xué);2003年

8 蔣文明;以減毒沙門氏菌為載體傳遞豬繁殖與呼吸綜合征病毒DNA疫苗的口服免疫應(yīng)答[D];南京農(nóng)業(yè)大學(xué);2004年

9 賈文影;新孢子蟲PO基因的真核表達(dá)及DNA疫苗的初步研究[D];延邊大學(xué);2010年

10 羅彬;犬瘟熱病毒H基因克隆分析及DNA疫苗研究[D];中國農(nóng)業(yè)科學(xué)院;2010年

本文編號：2178878